Compare Clorox Co (CLX) vs CVS Health Corp (CVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Clorox Co vs CVS Health Corp — how do they compare? Clorox Co trades at $108.39 (market cap $13.02B), while CVS Health Corp trades at $93.66 (market cap $122.36B). The key difference: CVS Health Corp is far larger — about 9.4× Clorox Co's market cap, and Clorox Co pays the higher dividend (4.64%). Which is the better fit depends on your goals.
| CLX | CVS | |
|---|---|---|
Market Cap | $13.02B | $122.36B |
Sector | Consumer Staples | Health |
52-Week High | $127.16 | $110.60 |
52-Week Low | $86.12 | $65.51 |
Enterprise Value | $18.40B | $184.71B |
Dividend Yield | 4.64% | 2.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Clorox (CLX) trades at $105.15, down 0.43% today, with a bullish technical signal from moving averages and strong momentum indicators. Recent Q2 2026 earnings beat expectations with EPS of $1.66, though Q4 2025 missed. The company reported fiscal 2025 revenue of $7.10 billion and net income of $810 million, with a high ROE of 285.64% but elevated P/B ratio of 141.28. Dividend increased to $1.25 per share, payable August 28, 2026.
Outlook is mixed: bullish technicals and profitability contrast with analyst caution (10.34% buy ratings) and a consensus price target of $97.50 below current price. Risks include inflation pressures and competitive threats from private labels. Upside hinges on execution of cost-saving initiatives and market share recovery.
CVS Health trades at $95.70, down 0.54% on the day, with a bearish technical signal and key support at $95. The company reported strong Q2 2026 earnings, beating estimates with EPS of $2.58 versus $1.87 expected, and raised its full-year guidance. Revenue growth remains robust, reaching $402.07 billion in 2025, though net income margin compressed to 1.18%. Analyst sentiment is overwhelmingly positive with a consensus price target of $115.00.
The outlook for CVS is cautiously optimistic, driven by operational improvements in its Aetna segment and raised cash flow guidance. Investment opportunities include potential upside to the consensus target, but risks involve margin pressures, regulatory changes impacting pharmacy benefits in 2027, and high debt levels. The stock's current valuation at a P/E of 25.25 may limit near-term gains if earnings growth slows.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Clorox Co
With a history dating back more than 100 years, Clorox now plays in a variety of categories across the consumer products space, including cleaning supplies, laundry care, trash bags, cat litter, charcoal, food dressings, water-filtration products, and natural personal-care products. Beyond its namesake brand, the firm's portfolio includes Liquid-Plumr, Pine-Sol, S.O.S, Tilex, Kingsford, Fresh Step, Glad, Hidden Valley, KC Masterpiece, Brita, and Burt's Bees. Just shy of 85% of Clorox's sales stem from its home turf.
Read more on CLX →About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →
